2012 年
1. Horikoshi M, Goto D, Seiji Segawa, Yohei Yoshiga, Keiichi Iwanami, Asuka Inoue, Yuki Tanaka,Matsumoto I, Sumida T.:
Activation of Invariant NKT cells with glycolipid ligand α-galactosylceramide ameliorates glucose-6phosphate isomerase peptide-induced arthritis.
PLoS One 7(12):e51215,2012
2. Sumida T, Iizuka M, Asahima H, Tsuboi H, Matsumoto I.:
Pathogenic role of anti-M3 muscarinic acetylcholine receptor immune response in Sjögren's syndrome.
Presse Med 41(9 Pt 2):e461-466,2012
3. Inoue A, Matsumoto I, Tanaka Y, Umeda N, Tanaka Y, Mihara M, Takahashi S, Sumida T.:
Murine tumor necrosis factor α-induced adipose-related protein (tumor necrosis factor α-inducedprotein 9) deficiency leads to arthritis via interleukin-6 overproduction with enhanced NF-κB, STAT-3
signaling, and dysregulated apoptosis of macrophages
Arthritis Rheum 64(12):3877-3885,2012
4. Thomas G, Grunewald P, Bach H, Cossarizza A, Matsumoto I.:
The STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy withoverlapping and distinct cellular functions.
Biol Cell 104(11):641-657,2012
5. Tsuboi H, Matsuo N, Iizuka M, Tsuzuki S, Kondo Y, Tanaka A, Moriyama M, Matsumoto I,Nakamura S, Sumida T.:
Analysis of IgG4 class switch-related molecules in IgG4-related disease.
Arthritis Res Ther 14(4):R171,2012
6. Yamaguchi T, Ito S, Takano Y, Umeda N, Goto M, Horikoshi M, Hayashi T, Goto D, Matsumoto I,Sumida T.:
A case of disseminated sporotrichosis treated with prednisolone, immunosuppressants, andtocilizumab under the diagnosis of rheumatoid arthritis.
Intern Med 51(15):2035-2039,2012
7. Hashizume M, Yoshida H, Tanaka K, Suzuki M, Matsumoto I, Sumida T, Mihira M.:
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in amouse arthritis model.
Arthritis Res Ther 14(2):R96,2012
8. Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K,Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, FujiiT, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N,Harigai M, for the REAL Study Group.:
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events inrheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Ann Rheum Dis 71(1):1820-1826,2012

9. Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T,Koike T, Ihata A, Ishigatubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T,Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M,for the REAL Study Group:
Time-dependent increased risk for serious infection from continuous use of TNF antagonists during
three years in rheumatoid arthritis patients.
Arthritis Care & Research 64(8):1125-1134,2012
10. Kawasaki A, Furukawa H, Kondo Y, Ito S, Hayashi T, Kusaoi M, Matsumoto I, Tohma S, Takasaki Y,Hashimoto H, Sumida T, Tsuchiya N.:
Association of PHRF1-IRF7 region polymorphism with clinical manifestations of systemic lupus
erythematosus in a Japanese population.
Lupus 21(8):890-5,2012
11. Hasebe N, Kawasaki A, Ito I, Kawamoto M, Hasegawa M, Fujimoto M, Furukawa H, Tohma S,Sumida T, Takehara K, Sato S, Kawaguchi Y, Tsuchiya N.:
Association of UBE2L3 polymorphisms with diffuse cutaneous systemic sclerosis in a Japanese
population.
Ann Rheum Dis 71(7):1259-60,2012
12. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T,Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T,Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K,Ohara H.:
Comprehensive Diagnostic Criteria (CDC criteria) for IgG4-related disease (IgG4-RD),2011
Mod Rheumatol 22:21-30,2012
13. Tanaka Y, Matsumoto I, Iwanami K, Inoue A, Umeda N, Tanaka Y, Sugihara M, Hayashi T, Ito S,Sumida T.
Six-transmembrane epithelial antigen of prostate4 (STEAP4) is expressed on monocytes/neutrophils,
and is regulated by TNF antagonist in patients with rheumatoid arthritis.
Clin Exp Rheumatol 30(1):99-102,2012
14. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, MimoriT, Tanaka Y, Tsubota Y, Toshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, IshigakiY, Azumi A, Kojima M, Nakamura S, Inoue D.:
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details.
Mod Rhumatol 22:1-14,2012
15. Tsuboi H, Nakamura Y, Iizuka M, Matsuo N, Matsumoto I, Sumida T.:
Generation and functional analysis of monoclonal antibodies against the second extracellular loop ofhuman M3 muscarinic acetylcholine receptor
Mod Rheumatol 22(2):264-271,2012
16. Kondo Y, Iizuka M, Wakamatsu E, Yao Z, Tahara M, Tsuboi H, Sugihara M,
Hayashi T, Yoh K, Takahiashi S, Matsumoto I, Sumida T.:
Overexpression of T-bet gene regulates murine autoimmune arthritis
Arthritis Rheum 64:162-172,2012

17. Tanaka Y, Matsumoto I, Iwanami K, Inoue A, Minami R, Umeda N, Kanamori A, Ochiai N,Miyazawa K, Sugihara M, Hayashi T, Goto D, Ito S, Sumida T.:
Six-transmembrane epithelial antigen of prostate4(STEAP4) is TNFalpha-induced protein that
regulates IL-6, Il-8, and cell proliferation in synovium from patients with rheumatoid srthritis
Mod Rheumatol 22:128-136,2012
18. Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, Takahashi A, Horita T, Atsumi T, IshiiT, Okamoto A, Fujio K, Hirakata M, Amano H, Kondo Y, Ito S, Takada K, Mimori A, Saito K,
Kamachi M, Kawaguchi Y, Ikari K, Mohammed W O, Matsuda K, Terao C, Ohmura K, Myouzen K,Hosono N, Tsunoda T, Nishimoto N, Mimori T, Matsuda F, Tanaka Y, Sumida T, Yamanaka H,
Takasaki Y, Koike T, Horiuchi T, Hayashi K, Kubo M, Kamatani N, Yamada R, Nakumura Y,
Yamamoto K.:
A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus
erythematosus in Japanese.
PLoS Genet 8(1): e1002455,2012